Scout24 AG

  • WKN: A12DM8
  • ISIN: DE000A12DM80
  • Land: Deutschland

Nachricht vom 17.02.2017 | 14:25

Scout24 AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Scout24 AG

17.02.2017 / 14:25
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Scout24 AG
Dingolfinger Str. 1 - 15
81673 Munich
Germany

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Morgan Stanley Wilmington, Delaware
United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
Morgan Stanley & Co. International plc

5. Date on which threshold was crossed or reached
14 Feb 2017

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 4.97 % 4.42 % 9.38 % 107600000
Previous notification 5.01 % 4.42 % 9.43 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN absolute in %
  direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
direct
(Sec. 21 WpHG)
indirect
(Sec. 22 WpHG)
DE000A12DM80 0 5343499 0.00 % 4.97 %
Total 5343499 4.97 %

b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
Right of recall over securities lending agreements jederzeit / at any time jederzeit / at any time 2095688 1.95 %
    Total 2095688 1.95 %

b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
Equity Swap Vom / From 20.02.2017 bis / to 17.11.2017 jederzeit / at any time Cash 2658590 2.47 %
      Total 2658590 2.47 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
Morgan Stanley % % %
Morgan Stanley Capital Management, LLC % % %
Morgan Stanley Domestic Holdings, Inc. % % %
Morgan Stanley & Co. LLC % % %
 
Morgan Stanley % % %
Morgan Stanley International Holdings Inc. % % %
Morgan Stanley International Limited % % %
Morgan Stanley UK Group % % %
Morgan Stanley Investments (UK) % % %
Morgan Stanley & Co. International plc 4.58 % % 9.00 %
 
Morgan Stanley % % %
MSDW Offshore Equity Services Inc. % % %
FUNDLOGIC SAS % % %

9. In case of proxy voting according to Sec. 22 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
 



17.02.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

EYEMAXX Real Estate AG: EYEMAXX begibt Wandelanleihe im Volumen von bis zu 20,376 Mio. Euro

Kupon:4,5%

Bezugsfrist: bis 12. April 2017 (12.00 Uhr)

Öffentliches Angebot:bis 18. April 2017 (12.00 Uhr)

Laufzeit:bis einschließlich 15. Dezember 2019

ISIN: DE000A2DAJB7

GBC im Fokus

Neovacs S.A.: Kursziel auf 3,30 € angehoben

In den letzten Monaten hatte die Neovacs S.A. einen positiven Newsflow. Im Vordergrund steht die Vertriebspartnerschaft für den chinesischen Markt, wodurch sich bis nach dem ersten Vermarktungsjahr Gesamterträge von bis zu 65 Mio. € ergeben können. Zudem verläuft der klinische Zulassungsprozess des IFNα-Kinoid zur Behandlung von SLE (Systemischer Lupus) und Dermatomyositis planmäßig. Wir haben in unsere Bewertung aktualisiert und ein Kursziel von 3,30 € je Aktie (bisher: 2,90 €) ermittelt. Das Rating lautet weiter KAUFEN.

Event im Fokus

65. m:access Analystenkonferenz

Datum: 06.04.2017
Zeit: 09:30 - 17:00 Uhr
Ort: Börse München
Karolinenplatz 6
80333 München

News im Fokus

Vonovia SE: 93,09 % der conwert-Aktionäre nehmen das Übernahmeangebot von Vonovia an

27. März 2017, 18:18

Aktueller Webcast

Manz AG

Annual Report 2016

30. März 2017

Aktuelle Research-Studie

Ergomed plc

Original-Research: Ergomed plc (von GBC AG): Kaufen

29. März 2017